Biography for John Carroll
John D. Carroll, Editor-in-Chief
John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
A team of investigators at the University of Queensland in Australia says it has found an inflammatory protein called PAR2 that builds up in the fat tissue of obese humans and rodents.
Morrisville, NC-based Gentris is setting up a new genomic biomarker testing service in Shanghai, a growing global hub for drug development.
A new study out of UCLA points to a potential biomarker for identifying which patients have the "fast" form of the disease and will need significant help early on.
Investigators at the University of Toronto say that the S100A7 protein can be used to flag precancerous oral lesions, precursors to cancer of the mouth, which is a particularly serious threat in Asia.
The hunt for new biomarkers that can help guide the diagnosis and, eventually, some method of treatment for Alzheimer's has spurred Big Pharma and non-profit groups to fund a careful investigation into the disease's links to Down syndrome.
The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
Researchers at Johns Hopkins say they've been able to track a pair of biomarkers that can shed light on a patient's risk of developing Alzheimer's and pinpoint the disease before telltale symptoms appear.
In a recent study, scientists with the University of Oregon tracked the release of nerve growth factor in saliva, finding for the first time that this protein typically linked to the survival, development and function of neurons could be an important player in understanding the body's response to stress.
While some investigators are seeking better ways to treat pancreatic cancer, others have been tracking biomarkers that can offer a more accurate way to identify the lethal disease earlier on, so patients can be treated while there's a greater chance of fighting the disease.
Pancreatic cancer has long remained one of the toughest targets in the oncology drug field. But an investigator says targeting a biomarker known as phosphatidylserine could greatly improve the odds of coming up with an effective therapy.